Symbiotec Pharmalab Limited (SYMBIOTEC)

Symbiotec Pharmalab Limited has submitted an intimation under Regulation 30(5) of the SEBI LODR Regulations, 2015. The company has authorized three Key Managerial Personnel (KMPs) to determine the materiality of events or information and make stock exchange disclosures. The authorized personnel comprise CMD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain.

• Disclosure filed pursuant to Regulation 30(5) of SEBI LODR Regulations, 2015 on September 01, 2026
• Authorized 3 Key Managerial Personnel to evaluate event materiality and stock exchange disclosures
• Designated KMPs include Chairman & MD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain

Symbiotec Pharmalab Limited has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to stock exchanges on September 01, 2026. The submission is made pursuant to Regulation 8(2) framed under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is a standard regulatory compliance filing with no impact on operations or financials.

• Filing submitted under Regulation 8(2) of SEBI PIT Regulations, 2015
• Adoption of Code of Practices and Procedures for Fair Disclosure of UPSI
• Intimation dated September 01, 2026 submitted to BSE (544889) and NSE (SYMBIOTEC)

Symbiotec Pharmalab Limited has announced the closure of its trading window for all designated persons and their immediate relatives effective Tuesday, September 01, 2026. The window will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The company stated that the specific date of the Board of Directors meeting to approve the results will be communicated in due course.

• Trading window closure effective from Tuesday, September 01, 2026
• Closure applies to all designated persons and immediate relatives pursuant to SEBI PIT Regulations
• Trading window to reopen 48 hours after declaration of Q1 results for the quarter ended June 30, 2026
• Board meeting date to approve financial results to be intimated separately